-+ 0.00%
-+ 0.00%
-+ 0.00%

PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 ADVANCED CANCER STUDY DATA DEMONSTRATING LONG-TERM SAFETY AND TOLERABILITY, AND DURABLE CLINICAL ACTIVITY IN MEK/BRAF-PRETREATED PATIENTS, PLUS PROTOCOL EXPANSION

Reuters·06/30/2026 11:00:02

Please log in to view news